论文部分内容阅读
作者用米托蒽醌(mitoxantrone)与大剂量阿糖胞苷(Ara-C)联合治疗44例难治性或复发性急性髓细胞白血病(AML)。米托蒽醌5mg/m~2/日静滴1小时、共5天。Ara-C 3g/m~2/12小时、静滴2小时,共6次。结果:16例(36%)获完全缓解(CR),12例(27%)在诱导化疗期间死亡(3例早期死亡,9例继发再障后死亡),16例(36%)耐药(6例原发性耐药,10例继发性耐药)。年龄小于50岁和体质良好者,其CR率高,第1次复发者比原发耐药者或2次以上复发者的疗效要好(CR率分别为45%和29%,P=0.27)。核型为inv(16)、t(8;21)、t(15;17)或二倍体者,其CR率也比其它核型异常者要高(分别为46%和19%,P=
The authors used mitoxantrone and high-dose cytarabine (Ara-C) in the combination of 44 patients with refractory or relapsed acute myeloid leukemia (AML). Mitoxantrone 5 mg/m~2/day intravenous infusion for 1 hour for 5 days. Ara-C 3g/m~2/12 hours, intravenous infusion 2 hours, 6 times in total. Results: 16 patients (36%) achieved complete remission (CR), 12 patients (27%) died during induction chemotherapy (3 early deaths, 9 secondary deaths after AA), and 16 (36%) drug resistance (6 primary drug resistance and 10 secondary drug resistance). The CR rate was higher in those who were under 50 years of age and had good physical fitness. The first relapse was better than the original drug resistance or more than two relapses (CR rates were 45% and 29%, respectively, P=0.27). Those with a karyotype of inv(16), t(8;21), t(15;17), or diploid had higher CR rates than those with other karyotype abnormalities (46% and 19%, respectively, P=